格列齐特联合阿卡波糖治疗2型糖尿病疗效观察

目的：评价格列齐特缓释片联合阿卡波糖治疗2型糖尿病的有效性及安全性。方法：65例2型糖尿病患者根据血糖水平分为3组,分别给予格列齐特缓释片30mg、60mg、120mg,同时联合阿卡波糖片150mg治疗,观察各组血糖、糖化血红蛋白（HbAlc）水平。结果：联合治疗后,全组HbAlc从（8.8±0.75）%下降到（6.83±0.75）%,空腹血糖（FPG）从（9.7±1.86）mmol·L~（-1）下降到（6.56±0.40）mmol·L~（-1）,餐后血糖（PPG）从（15.1±2.35）mmol·L~（-1）下降到（8.87±2.1）mmol·L~（-1）。治疗前后比较,差异有统计学意义（P〈0.01）。且各剂量级患者治疗后HbAlc、FPG、PPG均较治疗前明显下降（P〈0.01）。试验期间发生低血糖事件15次,与药物剂量无关。结论：格列齐特缓释片与阿卡波糖联合治疗可有效的降低2型糖尿病患者的HbAlc、FPG、PPG水平,实现HbAlc达标。

Efficacy of Combined Treatment with Gliclazide and Acarbose in Type 2 Diabetic Patients

Objective:To evaluate the efficacy and safety of combined treatment with gliclazide and acarbose in type 2 diabetic patients.Methods:65 patients with type 2 diabetes were enrolled in the trial.According to the level of blood glucose,the patients were divided into 3 groups,one is the dose of gliclazide 30mg,another is 60mg,the other is 120mg, combined with acarbose 150 mg,then observe HbAlc、fasting plasma glucose（FPG） and postprandial plasma glucose （PPG）.Results:Compared with the first,HbAI c was reduced from（8.8±0.75 ）%to（6.83±0.75 ）%;FPG from（9.7±1.86）mmol·L^-1 to（6.56±0.40）mmol·L^-1;PPG from（15.1±2.35）mmol·L^-1to（8.87±2.1）mmol·L^-1.15 cases occured hypoglycema.The hypoglycemia was not correlated with drug dosages.Conclusion:The combined treatment with gliclazide and acarbose in type 2 diabetic patients could effectively reduce HbAlc,FPG,PPG.